Prognostic nomogram for patients with unresectable pancreatic cancer treated with gemcitabine plus nab–paclitaxel or FOLFIRINOX: A post–hoc analysis of a multicenter retrospective study in Japan (NAPOLEON study)

BACKGROUND: No reliable nomogram has been developed until date for predicting the survival in patients with unresectable pancreatic cancer undergoing treatment with gemcitabine plus nab–paclitaxel (GnP) or FOLFIRINOX. METHODS: This analysis was conducted using clinical data of Japanese patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Shibuki, Taro, Mizuta, Toshihiko, Shimokawa, Mototsugu, Koga, Futa, Ueda, Yujiro, Nakazawa, Junichi, Komori, Azusa, Otsu, Satoshi, Arima, Shiho, Fukahori, Masaru, Makiyama, Akitaka, Taguchi, Hiroki, Honda, Takuya, Mitsugi, Kenji, Nio, Kenta, Ide, Yasushi, Ureshino, Norio, Shirakawa, Tsuyoshi, Otsuka, Taiga
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8722136/
https://www.ncbi.nlm.nih.gov/pubmed/34980029
http://dx.doi.org/10.1186/s12885-021-09139-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8722136/
https://www.ncbi.nlm.nih.gov/pubmed/34980029
http://dx.doi.org/10.1186/s12885-021-09139-y

Ejemplares similares